CRISPR Therapeutics Files 8-K for Undisclosed "Other Events"
Ticker: CRSP · Form: 8-K · Filed: Feb 13, 2024 · CIK: 1674416
Sentiment: neutral
Topics: 8-K Filing, Regulatory Filing, Other Events
TL;DR
**CRISPR Therapeutics filed an 8-K for "Other Events" on Feb 13, but the details are missing, so watch for updates!**
AI Summary
CRISPR Therapeutics AG filed an 8-K on February 13, 2024, reporting "Other Events" under Item 8.01. The filing indicates a material event occurred on this date, but the specific nature of these events is not disclosed within the provided document. This administrative filing serves to notify the SEC and investors of a development that is not covered by other standard 8-K items.
Why It Matters
An 8-K for "Other Events" signals that CRISPR Therapeutics AG has experienced a material event not covered by other specific 8-K items. Investors will need to await further disclosure to understand the implications, which could range from minor administrative changes to significant corporate developments.
Risk Assessment
Risk Level: medium — The filing indicates a material event occurred, but without specific details, the nature and impact on CRISPR Therapeutics AG's operations or financials remain unknown, creating uncertainty for investors.
Key Players & Entities
- CRISPR Therapeutics AG (company) — Registrant
- Switzerland (location) — State of Incorporation
- February 13, 2024 (date) — Date of earliest event reported
FAQ
What type of SEC filing is this document?
This document is an 8-K, a Current Report, filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the name of the registrant company?
The registrant company is CRISPR Therapeutics AG.
What is the date of the earliest event reported in this filing?
The earliest event reported occurred on February 13, 2024.
Under which item number are the events reported?
The events are reported under Item 8.01, titled "Other Events."
What is the registrant's state or other jurisdiction of incorporation?
The registrant's state or other jurisdiction of incorporation is Switzerland.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 15.1 · Accepted 2024-02-13 06:30:54
Filing Documents
- d787773d8k.htm (8-K) — 22KB
- 0001193125-24-032825.txt ( ) — 137KB
- crsp-20240213.xsd (EX-101.SCH) — 3KB
- crsp-20240213_lab.xml (EX-101.LAB) — 17KB
- crsp-20240213_pre.xml (EX-101.PRE) — 11KB
- d787773d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CRISPR Therapeutics AG Date: February 13, 2024 By: /s/ Samarth Kulkarni Samarth Kulkarni, Ph.D. Chief Executive Officer